Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine and CBT for Depression
NCT02289248Phase 1Completed
- Sponsor
- Yale University
- Start
- Feb 2015
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ketamine in major depressive disorder (MDD), sponsored by Yale University. Primary endpoint: Extinction Learning Task performance. Started Feb 2015; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02289248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289248.